A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 3, 2015, Pages 1671-1679

  Viljoen, J ^a   Azie, N ^b   Schmitt Hoffmann, A H ^c   Ghannoum, M ^d  

^a Knysna Provincial Hospital   (South Africa)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ISAVUCONAZOLE; ANTIFUNGAL AGENT; NITRILE; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; ATRIOVENTRICULAR BLOCK; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANDIDIASIS; FEMALE; FLU LIKE SYNDROME; GASTRITIS; GASTROENTERITIS; GASTROINTESTINAL DISEASE; HEMATURIA; HUMAN; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; LIFE EXPECTANCY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SEVERE RENAL IMPAIRMENT; TREATMENT DURATION; URINARY TRACT INFECTION; VOMITING; CANDIDIASIS; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; ESOPHAGEAL DISEASES; MICROBIOLOGY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; CANDIDIASIS; DOUBLE-BLIND METHOD; ESOPHAGEAL DISEASES; FEMALE; FLUCONAZOLE; HUMANS; MALE; NITRILES; PYRIDINES; TRIAZOLES;

EID: 84923240054     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04586-14     Document Type: Article

References (31)

1. Lortholary O, Petrikkos G, Akova M, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Cornely OA, Cuenca-Estrella M, Donnelly JP, Garbino J, Groll AH, Herbrecht R, Hope WW, Jensen HE, Kullberg BJ, Lass-Florl C, Meersseman W, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ. 2012. ESCMID∗ guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect 18(Suppl 7):68-77. http://dx.doi.org/10.1111/1469-0691.12042.
2. Shiboski C. High accuracy of common HIV-related oral disease diagnoses by non-oral health specialists in the AIDS Clinical Trial Group. AIDS Care, in press.
3. Ally R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, Hodges M, Troke P, Romero AJ. 2001. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33:1447-1454. http://dx.doi.org/10.1086/322653.
4. de Wet N, Llanos-Cuentas A, Suleiman J, Baraldi E, Krantz EF, Della Negra M, Diekmann-Berndt H. 2004. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 39:842-849. http://dx.doi.org/10.1086/423377.
5. de Wet N, Bester AJ, Viljoen J, Filho F, Suleiman JM, Ticona E, Llanos EA, Fisco C, Lau W, Buell D. 2005. A randomized, double blind, comparative trial of micafungin (FK463) versus fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 21:899-907. http://dx.doi.org/10.1111/j.1365-2036.2005.02427.x.
6. Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, Wible M, Henkel T. 2004. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 39:770-775. http://dx.doi.org/10.1086/423378.
7. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535. http://dx.doi.org/10.1086/596757.
8. Fichtenbaum CJ, Koletar S, Yiannoutsos C, Holland F, Pottage J, Cohn SE, Walawander A, Frame P, Feinberg J, Saag M, Van der Horst C, Powderly WG. 2000. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis 30:749-756. http://dx.doi.org/10.1086/313765.
9. Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi RN, Kauffman CA. 1994. Epidemiology of oral candidiasis in HIVinfected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 97:339-346. http://dx.doi.org/10.1016/0002-9343(94)90300-X.
10. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. 1996. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 173:219-225. http://dx.doi.org/10.1093/infdis/173.1.219.
11. Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE. 1997. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 24:28-34. http://dx.doi.org/10.1093/clinids/24.1.28.
12. Pagani JL, Chave JP, Casjka C, Glauser MP, Bille J. 2002. Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial. J Antimicrob Chemother 50:231-240. http://dx.doi.org/10.1093/jac/dkf101.
13. Pfaller MA, Jones RN, Castanheira M. 2014. Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011. Mycoses 57:602-611. http://dx.doi.org/10.1111/myc.12206.
14. Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T, Roehrle M, Beglinger C. 2006. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 50:279-285. http://dx.doi.org/10.1128/AAC.50.1.279-285.2006.
15. Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW. 2009. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother 53:3453-3461. http://dx.doi.org/10.1128/AAC.01601-08.
16. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. 2008. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 52: 1396-1400. http://dx.doi.org/10.1128/AAC.01512-07.
17. Illnait-Zaragozi MT, Martinez GF, Curfs-Breuker I, Fernández CM, Boekhout T, Meis JF. 2008. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother 52: 1580-1582. http://dx.doi.org/10.1128/AAC.01384-07.
18. Martin de la Escalera C, Aller AI, López-Oviedo E, Romero A, Martos AI, Cantón E, Peman J, Garcia Martos P, Martin-Mazuelos E. 2008. Activity of BAL 4815 against filamentous fungi. J Antimicrob Chemother 61:1083-1086. http://dx.doi.org/10.1093/jac/dkn076.
19. Verweij PE, González GM, Wiedrhold NP, Lass-Flörl C, Warn P, Heep M, Ghannoum MA, Guinea J. 2009. In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. J Chemother 21:272-281. http://dx.doi.org/10.1179/joc.2009.21.3.272.
20. Lepak AJ, Marchillo K, Vanhecker J, Andes DR. 2013. Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. Antimicrob Agents Chemother 57:6284-6289. http://dx.doi.org/10.1128/AAC.01355-13.
21. Lepak AJ, Marchillo K, Van Hecker J, Diekema D, Andes DR. 2013. Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model. Antimicrob Agents Chemother 57:5642-5648. http://dx.doi.org/10.1128/AAC.01354-13.
22. Luo G, Gebremariam T, Lee H, Edwards JE, Jr, Kovanda L, Ibrahim AS. 2014. Isavuconazole therapy protects immunosuppressed mice from mucormycosis. Antimicrob Agents Chemother 58:2450-2453. http://dx.doi.org/10.1128/AAC.02301-13.
23. Majithiya J, Sharp A, Parmar A, Denning DW, Warn PA. 2009. Efficacy of isavuconazole, voriconazole, and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother 63:161-166. http://dx.doi.org/10.1093/jac/dkn431.
24. Pfizer, Inc. 2011. Diflucan (fluconazole tablets) (fluconazole injection for intravenous infusion only) (fluconazole for oral suspension). Pfizer, Inc., New York, NY. http://www.accessdata.fda.gov/drugsatfda-docs/label/201 1/019949s051lbl.pdf.
25. Barbaro G, Barbarini G, Calderon W, Grisorio B, Alcini P, Di Lorenzo G. 1996. Fluconazole versus itraconazole for candida esophagitis in acquired immunodeficiency syndrome. Candida Esophagitis Gastroenterol 111:1169-1177.
26. Laine L, Dretler RH, Conteas CN, Tuazon C, Koster FM, Sattler F, Squires K, Islam MZ. 1992. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS: a randomized trial. Ann Int Med 117:655-660. http://dx.doi.org/10.7326/0003-4819-117-8-655.
27. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, Smietana JM, DiNubile MJ, Sable CA. 2002. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 113:294-299. http://dx.doi.org/10.1016/S0002-9343(02)01191-9.
28. Pfaller MA, Castanheira M, Messer SA, Rhomberg PR, Jones RN. 2014. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp. Diagn Microbiol Infect Dis 79:198-204. http://dx.doi.org/10.1016/j.diagmicrobio.2014.03.004.
29. Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M. 2013. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol 51:2608-2616. http://dx.doi.org/10.1128/JCM.00863-13.
30. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE, Infectious Diseases Society of America. 2004. Guidelines for treatment of candidiasis. Clin Infect Dis 38:161-189. http://dx.doi.org/10.1086/380796.
31. Cornely OA, Böhme A, Schmitt-Hoffmann A, Ullmann AJ. 26 January 2015. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother http://dx.doi.org/10.1128/AAC.04569-14.